BioIntelliSense Introduces the 5G-enabled BioHub Connectivity Gateway to Its Remote Patient Monitoring (RPM) Data Service

Auto-detection of the FDA-cleared BioSticker™ on-body sensor, along with compatible 3rd party medical devices, for seamless and secure vital sign data transmission


The BioHub preconfigured connectivity gateway is built with a Qualcomm 5G chip set for auto-detection of the BioSticker™ on-body sensor, along with compatible 3rd party medical devices. This secure gateway enables near real-time encrypted data transmission of minute-level vital signs to the BioIntelliSense BioCloud for algorithmic analysis and reporting.

The BioHub offers effortless remote data capture, with an embedded cellular connectivity and data plan, to support Remote Patient Monitoring (RPM) programs for complex care, postacute recovery and clinical trials at scale. It has been designed for a simplistic ‘plug it in and forget it’ patient experience, removing the complexity of Bluetooth® pairing, for continuous health monitoring in the home and clinical settings.

BioIntelliSense has partnered with KORE, an industry-leader in IoT solutions and managed services, to provide connectivity access with over 24 global carriers. “With the KORE Wireless Group as a trusted advisor, BioIntelliSense successfully achieved BioHub certification on the AT&T network to support our U.S. launch and future market expansion” said James Mault, MD, CEO of BioIntelliSense.

“All of us at KORE are excited to support the pioneering work being done at BioIntelliSense. KORE Health is now our fastest growing industry segment with Remote Patient Monitoring and related use cases that we support represent a terrific opportunity to improve the efficacy and efficiency of healthcare delivery,” said Romil Bahl, President and CEO of KORE.
About BioIntelliSense

BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures minute-to-minute vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The FDA-cleared BioSticker™ device makes remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians will now have access to high-resolution patient trending and reporting to enable medical grade care in the home.

For more information on how BioIntelliSense is redefining remote patient monitoring through medical-grade and cost-effective data services, please contact us at info@biointellisense.com or visit our website at BioIntelliSense.com.

MEDIA CONTACT:
BioIntelliSense, Inc.
Carolyn Walsh
Chief Commercial Officer
cwalsh@BioIntelliSense.com